Last reviewed · How we verify
NCT03930940: RICH
Remote Ischemic Conditioning for Intracerebral Hemorrhage
Phase 1 trial testing remote ischemic conditioning in Intracerebral Hemorrhage in 40 participants. Completed in 10 February 2020.
17 November 2019
Quick facts
| Lead sponsor | Capital Medical University |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 40 |
| Start date | 9 July 2019 |
| Primary completion | 17 November 2019 |
| Estimated completion | 10 February 2020 |
| Sites | 1 location across China |
Drugs / interventions tested
- remote ischemic conditioning
- Regular treatment — full drug profile →
Conditions studied
- Intracerebral Hemorrhage — all drugs for Intracerebral Hemorrhage →
Sponsor
Capital Medical University
Who can join
Adults 18 to 80, any sex, with Intracerebral Hemorrhage. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Spontaneous intracerebral hemorrhage (ICH) results from the rupture of small vessels damaged by chronic hypertension, amyloid angiopathy or other disease. Hematoma volume has been demonstrated to be strongly correlated with the severity of white matter injury and conditions in ICH patients. In the past decades, surgical clot evacuation and stereotactic or endoscopic clot aspiration with thrombolytic drugs have been investigated for the treatment of ICH, however, none of them have been demonstrated to be effective. As such, medical management remains the standard of care for most patients with ICH, leading to ICH as the least treatable form of stroke. Remote ischemic conditioning (RIC) has been found to have neuroprotective effects by in patients with ischemic stroke. In addition, animal studies show that RIC is safe in ICH model and it could accelerate the absorption of hematoma. Therefore, the investigators plan to undertake this study to evaluate the safety of RIC in patients with ICH, and planned for future study to determine if treatment with RIC can improve the outcome of patients with ICH. In this study, our main objectives are: 1) to evaluated the safety of RIC, by determining the treatment related adverse events, in patients with ICH; and 2) to determine the preliminary effects of RIC on hematoma absorption and cerebral edema. The investigators hypothesize that RIC is well-tolerated and has minimal serious adverse effects in patients with ICH; and that treatment with RIC will accelerate the absorption of hematoma and improve patients' functional outcomes. Results of this study can potentially bring into account new means to improve the outcomes of ICH patients.
Publications & conference data
7 peer-reviewed publications reference this trial (live from Europe PMC):
-
Safety and efficacy of remote ischemic conditioning for the treatment of intracerebral hemorrhage: A proof-of-concept randomized controlled trial.
Zhao W, Jiang F, Li S, Liu G, et al · · 2022 · cited 21× · PMID 33739197 · DOI 10.1177/17474930211006580 -
Erythrophagocytosis by Microglia/Macrophage in Intracerebral Hemorrhage: From Mechanisms to Translation.
Liu J, Zhu Z, Leung GK. · · 2022 · cited 19× · PMID 35237132 · DOI 10.3389/fncel.2022.818602 -
Remote Ischemic Conditioning for Intracerebral Hemorrhage (RICH-1): Rationale and Study Protocol for a Pilot Open-Label Randomized Controlled Trial.
Zhao W, Jiang F, Li S, Wu C, et al · · 2020 · cited 15× · PMID 32411082 · DOI 10.3389/fneur.2020.00313 -
New targets in spontaneous intracerebral hemorrhage.
Chiang PT, Tsai LK, Tsai HH. · · 2025 · cited 12× · PMID 39325041 · DOI 10.1097/wco.0000000000001325 -
Dabigatran etexilate versus warfarin in cerebral venous thrombosis in Chinese patients (CHOICE-CVT): An open-label, randomized controlled trial.
Ma H, Gu Y, Bian T, Song H, et al · · 2024 · cited 12× · PMID 38353219 · DOI 10.1177/17474930241234749 -
Conditioning medicine for ischemic and hemorrhagic stroke.
Hess DC, Khan MB, Kamat P, Vaibhav K, et al · · 2021 · cited 6× · PMID 34414362 -
Pilot Study of Remote Ischemic Conditioning in Acute Spontaneous Intracerebral Hemorrhage.
Jarrahi A, Shah M, Ahluwalia M, Khodadadi H, et al · · 2022 · cited 4× · PMID 35645722 · DOI 10.3389/fnins.2022.791035
Verify or expand the search:
- PubMed search for NCT03930940
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of remote ischemic conditioning
Trials testing the same drug.
- NCT07270887 — The Long-term Effect of Remote Ischemic Conditioning on Main Organs in ASVCD Patients With Very High Risks · recruiting
- NCT06931535 — Remote Ischemic Conditioning for Acute Moderate Posterior Ischemic Stroke · NA · recruiting
- NCT06826144 — Chronic Remote Ischemic Conditioning in Small Infarctions Associated with Stent-assisted Coiling of Unruptured Intracran · NA · not yet recruiting
- NCT05599009 — Remote Ischemic Conditioning and Dynamic Cerebral Autoregulation in Patients With Intracranial and Extracranial Arterios · NA · unknown
- NCT05263531 — Remote Ischemic Conditioning for Motor Recovery After Acute Ischemic Stroke · NA · unknown
Other recruiting trials for Intracerebral Hemorrhage
Currently open trials in the same condition.
- NCT07458880 — Triple Antihypertensive Medication After Intracerebral Hemorrhage for Blood Pressure Control · NA · recruiting
- NCT07365150 — Precision Use of TXA in Intracerebral Hemorrhage · NA · recruiting
- NCT07246473 — Non-invasive Ultrasound and Hematoma Clearance After Intracerebral Hemorrhage · NA · recruiting
- NCT07455201 — Evaluating a Prototype CT Scan for ICH Evacuation · NA · recruiting
- NCT07187687 — TrIal of Early Minimally Invasive Catheter Evacuation With Thrombolysis in IntraCerebral Hemorrhage · NA · recruiting
Other Capital Medical University trials
Trials by the same sponsor.
- NCT07379437 — Haematococcus Pluvialis Astaxanthin for Brain Aging · NA · not yet recruiting
- NCT07531394 — Safety and Efficacy of Remote Ischemic Conditioning in Patients With Acute Myocardial Injury Following Acute Ischemic St · Phase 3 · not yet recruiting
- NCT07509645 — Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Post · Phase 3 · recruiting
- NCT07513233 — Anisodine Hydrobromide for Patients With Acute Ischemic Stroke Undergoing Endovascular Therapy (HEAL) · Phase 1 · not yet recruiting
- NCT07495358 — Development and Usability Evaluation of a Knowledge Graph-Based Symptom Management System for Patients With Breast Cance · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03930940 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Capital Medical University
- Last refreshed: 11 February 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03930940.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing